comparemela.com

Latest Breaking News On - Novel antitumor agents - Page 1 : comparemela.com

Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Ryvu PRMT5 inhibitors show potential best-in-class profiles, including a strong antiproliferative effect on MTAP-deleted cell lines and a good safety window.

Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024

/PRNewswire/ Laekna (2105.HK) announced that the company has presented two internally-discovered preclinical candidates, in addition to a poster.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.